National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed castration-resistant prostate cancer with symptomatic bone metastases.
Minimum detectable skeletal lesion count of 3.
Eligible to receive Xofigo.
At least 18 years of age.
ECOG performance status ≤ 3.
Ability to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
You may not be if
Predominant visceral metastatic disease.
Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
Concurrent alternative radiopharmaceuticals
Inability to maintain stationary supine pose for 45-60 minutes
Eligibility Criteria - Physicians:
Medical Oncologist or Radiation Oncologist at Siteman Cancer Center.
Treating patients with prostate cancer.
Willing to complete Physician Questionnaire during participation.
